Development of the MIPS/Doherty mRNA SARS-CoV-2 vaccine for Phase 1 clinical trial

The grant will (i) advance the development of the MIPS/Doherty mRNA SARS-CoV-2 vaccine, (ii) simultaneously begin the development of mRNA vaccine manufacturing expertise at the local Victorian contract manufacturer, IDT Australia Ltd. (IDT), and (iii) purchase equipment for manufacture of formulated vaccine. Specifically, the funding will support the manufacture a mRNA vaccine fit for human use in our MRFF-funded Phase 1 clinical trial, provide staff and materials at MIPS to manage the project, support technology transfer to IDT, develop quality assurance procedures and evaluate the potency and stability of manufactured products.